2023 was a landmark year for Alzheimer’s disease research, including advancements in treatment, risk factors and diagnosis.
Alzheimer’s “Type 3 diabetes”
Alzheimer's disease, commonly referred to as a neurodegenerative disorder, has been increasingly associated with metabolic dysfunctions similar to diabetes, leading to its unofficial designation as "type 3 diabetes." This term stems from the shared molecular and cellular features between diabetes and Alzheimer's.In particular, insulin, a hormone critical for regulating blood sugar levels, is also involved in the formation of amyloid plaques and the phosphorylation of tau proteins in the brain, both of which are hallmarks of Alzheimer's disease.The concept of type 3 diabetes further gains credibility due to the esta
